Advances in the pharmacological treatment of gastro-oesophageal cancer

Drugs and Aging

Volumn 26, Issue 8, 2009, Pages 627-646

  Wagner, Anna Dorothea ^a,c   Wedding, Ulrich ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; TRASTUZUMAB; UFT;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FATALITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GERIATRIC ASSESSMENT; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LETHARGY; LEUKOPENIA; LOW DRUG DOSE; LYMPHADENECTOMY; MEDICAL DECISION MAKING; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH PERFORATION; STOMATITIS; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ESOPHAGEAL NEOPLASMS; GERIATRIC ASSESSMENT; HUMANS; PALLIATIVE CARE; STOMACH NEOPLASMS;

EID: 69149087317     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11315740-000000000-00000     Document Type: Review

References (87)

1. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003; 56 (1): 1-9 (Pubitemid 36183309)
2. Ferlay J, Bray J, Pisani P, et al. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. Version 1.0 ed. Lyon: IARC Press, 2001
3. Zitierweise. Krebs in Deutschland 2003-2004. Häufigkeiten und Trends. 6. überarbeitete Auflage. Berlin: Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen, Krebsregister in Deutschland e. V. (Hrsg), 2008
4. Ries LAG, Melbert D, Krapcho M, et al., editors. SEER Cancer statistics review, 1975-2005 [based on November 2007 SEER data submission, posted to the SEER web site]. Bethesda (MD): National Cancer Institute, 2008 [online]. Available from URL: http://seer.cancer.gov/csr/1975- 2005 [Accessed 2009 Jun 9]
5. Yancik R, Ries LA. Aging and cancer in America: demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 2000; 14 (1): 17-23 (Pubitemid 30078429)
6. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer 2002; 94 (10): 2766-2792
7. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21 (7): 1383-1389 (Pubitemid 46606420)
8. Saito H, Osaki T, Murakami D, et al. Effect of age on prognosis in patients with gastric cancer. ANZ J Surg 2006; 76 (6): 458-461 (Pubitemid 43846467)
9. Buffart TE, Carvalho B, Hopmans E, et al. Gastric cancers in young and elderly patients show different genomic profiles. J Pathol 2007; 211 (1): 45-51 (Pubitemid 46092028)
10. Ubenstein LZ, Josephson KR, Wieland GD, et al. Effectiveness of a geriatric evaluation unit: a randomized clinical trial. N Engl J Med 1984; 311 (26): 1664-1670
11. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16 (4): 1582-1587 (Pubitemid 28175784)
12. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 20 (2): 494-502 (Pubitemid 34072534)
13. Wedding U, Ködding D, Pientka L, et al. Physicians judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Crit Rev Oncol Hematol 2007; 64: 1-9 (Pubitemid 47362733)
14. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the Task Force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005; 55 (3): 241-252 (Pubitemid 41219694)
15. Overcash JA, Beckstead J, Extermann M, et al. The abbreviated comprehensive geriatric assessment (aCGA): a retrospective analysis. Crit Rev Oncol Hematol 2005; 54 (2): 129-136 (Pubitemid 40544950)
16. Roehrig B, Hoeffken K, Pientka L, et al. How many and which items of activities of daily living (ADL) and instrumental activities of daily living (IADL) are necessary for screening? Crit Rev Oncol Hematol 2007; 62 (2): 164-171
17. Winograd CH, Gerety B, Chung M, et al. Screening for frailty: criteria and predictors of outcomes. J Am Geriatr Soc 1991; 39 (8): 778-784
18. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base report on poor survival of US gastric carcinoma patients treated with gastrectomy. 5th ed. In: American Joint Committee on Cancer staging, proximal disease, and the 'different disease' hypothesis. Cancer 2000; 88 (4): 921-932
19. Siewert JR, Bottcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228 (4): 449-461 (Pubitemid 30194389)
20. Cunningham D, Oliveira J. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 Suppl. 2: ii23-4
21. Gastric cancer treatment. Bethesda (MD): National Cancer Institute, 2008 May 16 [online]. Available from URL: http://www.cancer.gov/cancertopics/pdq/ treatment/gastric/ HealthProfessional/page8 [Accessed 2008 Oct 15]
22. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355 (1): 11-20
23. Macadam R, Sarela A, Wilson J, et al. Bone marrow micrometastases predict early post-operative recurrence following surgical resection of oesophageal and gastric carcinoma. Eur J Surg Oncol 2003; 29 (5): 450-454 (Pubitemid 36748589)
24. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345 (10): 725-730 (Pubitemid 34936653)
25. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35 (7): 1059-1064
26. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 2002; 168 (11): 597-608 (Pubitemid 36355892)
27. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials: a study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000; 11 (7): 837-843 (Pubitemid 30687895)
28. Nakajima T, Kinoshita T, Nashimoto A, et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007; 94 (12): 1468-1476 (Pubitemid 350275624)
29. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357 (18): 1810-1820 (Pubitemid 350044801)
30. Ajani JA, Faust J, Ikeda K, et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005; 23 (28): 6957-6965 (Pubitemid 46260282)
31. Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07- FFCD 9703 [abstract]. J Clin Oncol 2007; 25 (18S): 4510
32. Wagner AD, Grothe W, Behl S, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2005; (2): CD004064
33. Ilson DH. Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol 2007; 25 (22): 3188-3190
34. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15 (1): 110-115 (Pubitemid 27021524)
35. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34 (8): 1274-1281 (Pubitemid 28342121)
36. McGavin JK, Goa KL. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. Drugs 2001; 61 (15): 2309-2326 (Pubitemid 34074809)
37. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001; 40 (2): 85-104
38. European Medicines Agency. Capecitabine SMPC: scientific discussion [online]. Available from URL: http://www.emea. europa.eu/humandocs/PDFs/EPAR/ Xeloda/282200en6.pdf [Accessed 2008 Oct 01]
39. Cassidy J, Twelves C, Cameron D, et al. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 1999; 44 (6): 453-460 (Pubitemid 29501014)
40. Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999; 5 (7): 1696-1702 (Pubitemid 29334448)
41. Kang Y, Kang WK, Shin DB, et al. Randomized phase III trial of capecitabine/cisplatin (XP) versus continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results [abstract]. J Clin Oncol 2006; 24 (18S): LBA4018
42. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358 (1): 36-46
43. Okines AF, Norman AR, McCloud PI, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine- based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. Epub 2009 May 27
44. Kubota T. The role of S-1 in the treatment of gastric cancer. Br J Cancer 2008; 98 (8): 1301-1304 (Pubitemid 351543589)
45. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9 (3): 215-221
46. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21 (1): 54-59
47. Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS). 6th ASCO GI Cancer Symposium; 2009 Jan 15-17; San Francisco (CA). Chestnut Hill (MA): American Society of Clinical Oncology, 2009
48. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26 (9): 1435-1442
49. Bouche O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803. J Clin Oncol 2004; 22 (21): 4319-4328 (Pubitemid 41199650)
50. Moehler M, Eimermacher A, Siebler J, et al. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 2005; 92 (12): 2122-2128 (Pubitemid 40973775)
51. Pozzo C, Barone C, Szanto J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004; 15 (12): 1773-1781 (Pubitemid 40017161)
52. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19 (8): 1450-1457
53. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24 (31): 4991-4997 (Pubitemid 46631401)
54. Tebbutt NC, Norman A, Cunningham D, et al. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophagogastric cancer. Ann Oncol 2002; 13 (10): 1568-1575 (Pubitemid 35339322)
55. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18 (14): 2648-2657 (Pubitemid 30465650)
56. Field K, Michael M, Leong T. Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 2008; 68 (3): 299-317 (Pubitemid 351227347)
57. Kollmannsberger C, Quietzsch D, Haag C, et al. A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000; 83 (4): 458-462 (Pubitemid 30487857)
58. Murad AM, Petroianu A, Guimaraes RC, et al. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol 1999; 22 (6): 580-586 (Pubitemid 30266056)
59. Thuss-Patience PC, Kretzschmar A, Repp M, et al. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 2005; 23 (3): 494-501 (Pubitemid 46237444)
60. Ridwelski K, Fahlke J, Kettner E, et al. Docetaxel-cisplatin (DC) vs 5-fluorouracil-leucovorin-cisplatin (FLC) as firstline treatment for locally advanced or metastatic gastric cancer: preliminary results of a phase III study [abstract]. J Clin Oncol 2008; 26 (18S): 4512
61. Wagner AD, Wedding U, Kuss O, et al. Docetaxel for advanced gastric cancer? J Clin Oncol 2007; 25 (17): 2490-1; author reply 2491-2493
62. Wedding U, Honecker F, Bokemeyer C, et al. Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 2007; 14 (1): 44-56 (Pubitemid 46168965)
63. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345 (15): 1091-1097
64. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004; 15 (9): 1330-1338 (Pubitemid 39302467)
65. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/ leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24 (25): 4085-4091 (Pubitemid 46622283)
66. Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/ fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 2008; 26 (9): 1443-1451
67. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285 (21): 2750-2756 (Pubitemid 32525372)
68. Carey EC, Walter LC, Lindquist K, et al. Development and validation of a functional morbidity index to predict mortality in community-dwelling elders. J Gen Intern Med 2004; 19 (10): 1027-1033 (Pubitemid 39431139)
69. Lee SJ, Lindquist K, Segal MR, et al. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006; 295 (7): 801-808 (Pubitemid 43244307)
70. Trumper M, Ross PJ, Cunningham D, et al. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials. Eur J Cancer 2006; 42 (7): 827-834
71. Graziano F, Santini D, Testa E, et al. A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. Br J Cancer 2003; 89 (8): 1428-1432 (Pubitemid 37386596)
72. Santini D, Graziano F, Catalano V, et al. Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. BMC Cancer 2006; 6: 125 (Pubitemid 43884147)
73. Nardi M, Azzarello D, Maisano R, et al. FOLFOX-4 regimen as fist-line chemotherapy in elderly patients with advanced gastric cancer: a safety study. J Chemother 2007; 19 (1): 85-89 (Pubitemid 46255477)
74. Abbrederis K, Azzarello D, Maisano R, et al. Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer: results of a phase II study in elderly patients or patients with impaired performance status. Crit Rev Oncol Hematol 2008; 66 (1): 84-90
75. Liu ZF, Guo QS, Zhang XQ, et al. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. Am J Clin Oncol 2008; 31 (3): 259-263
76. Lee JL, Kang YK, Kang HJ, et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 2008; 99 (4): 584-590
77. Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 2002; 236 (1): 37-42 (Pubitemid 34686448)
78. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24 (33): 5201-5206 (Pubitemid 46631363)
79. Takehana T, Kunitomo K, Suzuki S, et al. Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol 2003; 1 (6): 438-445 (Pubitemid 37413607)
80. Tokunaga A, Onda M, Okuda T, et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 1995; 75 (6 Suppl.): 1418-1425
81. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24 (30): 4922-4927 (Pubitemid 46630921)
82. Doi T, Koizumi W, Siena S, et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer [abstract]. Proc Am Soc Clin Oncol 2003; 22: 1036
83. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007; 18 (3): 510-517 (Pubitemid 46359631)
84. Moehler M, Trarbach T, Seuferlein T, et al. Cetuximab with irinotecan/Na-Fa/5-FU as first-line treatment in advanced gastric cancer: preliminary results of a nonrandomised multi-centre AIO phase II study. Proceedings of the American Society of Clinical Oncology: 2008 Gastrointestinal Cancers. J Clin Oncol 2008; 26 (18S): 112
85. Lordick F, Lorenzen S, Hegewisch-Becker S, et al. Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group [abstract]. J Clin Oncol 2007; 25 (18S): 4526
86. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16 (2): 273-278 (Pubitemid 40309309)
87. Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) [abstract no. LBA4509]. J Clin Oncol 2009; 27 Suppl.: 18s